mhurhangee/patent-ind-claim-en huggingface dataset:
A manufacturing method for a hydrogel contact lens comprising: a first step of preparing a hydrogel contact lens substrate; swelling the hydrogel contact lens substrate by immersing the hydrogel contact lens substrate in an alcohol solution; and a second step of immersing the hydrogel contact lens substrate in a surface-modifying solution including a sodium hyaluronate compound, a hydrophilic monomer, and a crosslinking agent for at least 1 hour, wherein the surface-modifying solution includes 0.05 to 2 wt% of the hyaluronate compound, 0.2 to 10 wt% of the hydrophilic monomer, and 0.001 to 0.5 wt% of an initiator, and 87.5 to 99.5 wt% of water, and the crosslinking agent has a content of 0.02 to 0.05 mol per 1 mol of the hydrophilic monomer. a first step of preparing a hydrogel contact lens substrate; swelling the hydrogel contact lens substrate by immersing the hydrogel contact lens substrate in an alcohol solution; and a second step of immersing the hydrogel contact lens substrate in a surface-modifying solution including a sodium hyaluronate compound, a hydrophilic monomer, and a crosslinking agent for at least 1 hour, wherein the surface-modifying solution includes 0.05 to 2 wt% of the hyaluronate compound, 0.2 to 10 wt% of the hydrophilic monomer, and 0.001 to 0.5 wt% of an initiator, and 87.5 to 99.5 wt% of water, and the crosslinking agent has a content of 0.02 to 0.05 mol per 1 mol of the hydrophilic monomer.
A variable geometry structure comprising: a flexural element ; a tensioning element that has a fixed length and consists of a material with normal elastic properties; and an actuator for adjusting the tensioning element to change the load placed on the flexural element , thereby changing the geometry of the variable geometry structure , the actuator is affixed to the flexural element , the actuator comprises an actuating mechanism which is attached to a proximal end of the tensioning element , the actuator is configured to adjust the tensioning element by pulling the tensioning element ; characterised in that the tensioning element and the flexural element are connected at their distal ends ; and the actuator is operable to change the tensioning element between: (i) a free position where the tensioning element is not under tension and thus no load is placed on the flexural element, the flexural element being curved downwards away from the tensioning element when unstressed; (ii) a first configuration where the flexural element is substantially planar and stressed in bending; and (iii) a second configuration where the flexural element is curved upwards towards the tensioning element and stressed in bending, the second configuration placing a higher load on the flexural element than the first configuration. a flexural element ; a tensioning element that has a fixed length and consists of a material with normal elastic properties; and an actuator for adjusting the tensioning element to change the load placed on the flexural element , thereby changing the geometry of the variable geometry structure , the actuator is affixed to the flexural element , the actuator comprises an actuating mechanism which is attached to a proximal end of the tensioning element , the actuator is configured to adjust the tensioning element by pulling the tensioning element ; characterised in that the tensioning element and the flexural element are connected at their distal ends ; and the actuator is operable to change the tensioning element between: (i) a free position where the tensioning element is not under tension and thus no load is placed on the flexural element, the flexural element being curved downwards away from the tensioning element when unstressed; (ii) a first configuration where the flexural element is substantially planar and stressed in bending; and (iii) a second configuration where the flexural element is curved upwards towards the tensioning element and stressed in bending, the second configuration placing a higher load on the flexural element than the first configuration. (i) a free position where the tensioning element is not under tension and thus no load is placed on the flexural element, the flexural element being curved downwards away from the tensioning element when unstressed; (ii) a first configuration where the flexural element is substantially planar and stressed in bending; and (iii) a second configuration where the flexural element is curved upwards towards the tensioning element and stressed in bending, the second configuration placing a higher load on the flexural element than the first configuration.
A flow cytometry method for evaluating a biological material sample for unassociated virus-size particles of a viral type selected from the group consisting of an adenovirus viral type and an adeno-associated virus viral type, the method comprising: subjecting to flow cytometry a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain capable of binding, directly or indirectly, with an epitope of the viral type, the flow cytometry comprising: flowing the fluid sample through a flow cell of a flow cytometer; subjecting the fluid sample flowing through the flow cell to excitation radiation capable of causing a fluorescent emission response from the fluorescent antibody stain; and detecting radiation from the flow cell within a wavelength range of the fluorescent emission and evaluating the detected radiation to identify detection events indicative of passage through the flow cell of unassociated labeled particles of virus size including a said virus-size particle of the viral type bound with a portion of the fluorescent antibody stain; wherein the fluid sample as fed to the flow cytometer comprises a concentration of the fluorescent antibody stain free in solution and not bound in the unassociated labeled particles in a range of from 0.5 micrograms per milliliter to 10 micrograms per milliliter and a total concentration of the florescent antibody stain in a range of from 0.5 microgram per milliliter to 10 micrograms per milliliter. flowing the fluid sample through a flow cell of a flow cytometer; subjecting the fluid sample flowing through the flow cell to excitation radiation capable of causing a fluorescent emission response from the fluorescent antibody stain; and detecting radiation from the flow cell within a wavelength range of the fluorescent emission and evaluating the detected radiation to identify detection events indicative of passage through the flow cell of unassociated labeled particles of virus size including a said virus-size particle of the viral type bound with a portion of the fluorescent antibody stain; wherein the fluid sample as fed to the flow cytometer comprises a concentration of the fluorescent antibody stain free in solution and not bound in the unassociated labeled particles in a range of from 0.5 micrograms per milliliter to 10 micrograms per milliliter and a total concentration of the florescent antibody stain in a range of from 0.5 microgram per milliliter to 10 micrograms per milliliter.
A glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment of short bowel syndrome (SBS) in a human subject receiving a parenteral support (PS) regimen, wherein the treatment comprises adjusting a volume of parenteral support (PS) each week by: (i) administering to the subject a GLP-2 analogue for a time sufficient to grow and/or improve the function of the small intestine of the subject; (ii) following step (i), reducing a volume of the parenteral support (PS) regimen in response to improved function of the small intestine; and (iii) optionally repeating steps (i) and (ii) in response to the subject demonstrating improved function over time as a result of further growth of the small intestine; wherein in the above method, step (ii) comprises the steps of: (a) determining the current weekly volume of PS required by the subject at that point in the treatment; (b) measuring a current urine volume produced by the subject and comparing the current urine volume to a baseline urine volume determined at the start of the GLP-2 therapy to determine an absolute increase in urine production per day; and (c) reducing the volume of the PS where the subject demonstrates improved function of the small intestine as indicated by an absolute increase in urine production per day; wherein the new reduced weekly calculated PS volume for the subject equals the current weekly PS volume minus 7 times the absolute increase in daily urine volume from baseline; wherein the method comprises administering the calculated PS volume to the subject; and wherein the method comprises an initial step of determining the baseline urine volume and/or determining the daily urine volume of the subject. (i) administering to the subject a GLP-2 analogue for a time sufficient to grow and/or improve the function of the small intestine of the subject; (ii) following step (i), reducing a volume of the parenteral support (PS) regimen in response to improved function of the small intestine; and (iii) optionally repeating steps (i) and (ii) in response to the subject demonstrating improved function over time as a result of further growth of the small intestine; (a) determining the current weekly volume of PS required by the subject at that point in the treatment; (b) measuring a current urine volume produced by the subject and comparing the current urine volume to a baseline urine volume determined at the start of the GLP-2 therapy to determine an absolute increase in urine production per day; and (c) reducing the volume of the PS where the subject demonstrates improved function of the small intestine as indicated by an absolute increase in urine production per day; wherein the new reduced weekly calculated PS volume for the subject equals the current weekly PS volume minus 7 times the absolute increase in daily urine volume from baseline; wherein the method comprises administering the calculated PS volume to the subject; and wherein the method comprises an initial step of determining the baseline urine volume and/or determining the daily urine volume of the subject.
Plug-in connector for connecting at least one fluid line to another fluid line or to an apparatus connector, comprising a housing having a passage duct , wherein one end of the housing is configured as a ferrule portion for plugging in a mating plug-in connector and has latching means for releasably fixing the mating plug-in connector , wherein the latching means are a component part of an adapter sleeve which is able to be plugged into the ferrule portion and is held in the ferrule portion by means of radially elastic form-fit elements , and has a passage opening for a plug shank of the mating plug-in connector ; and also the latching means being formed by at least two latching arms that are radially elastic in terms of a longitudinal central axis (X-X) of the plug-in connector and being configured on the circumference of the adapter sleeve by slotshaped reliefs in the sleeve wall of said adapter sleeve , and these latching arms on the free end thereof having latching cams that run radially in the direction towards the longitudinal central axis (X-X); wherein the form-fit elements are composed of radially elastic latching appendages which are configured on the external circumference of the adapter sleeve so as to be between the latching arms and in the plugged-in state engage in a form-fitting and latching manner in first clearances in the circumferential wall of the ferrule portion , characterized in that the latching cams of the latching arms from the longitudinal central axis (X-X) have a radial spacing that is smaller than an internal radius of the passage opening , and also a radial spacing of the latching arms in relation to the longitudinal central axis (X-X), at least in a region adjacent to the latching cams of said latching arms , is equal to the internal diameter of the passage opening or smaller than the internal diameter of the passage opening , so that the latching cams of the latching arms in the plugged-in state of the mating plug-in connector can engage in a latching groove of the plug shank of the mating plug-in connector .
Passenger seat system for a cabin of a means of transportation , having: - a plurality of passenger seats which are disposed behind one another and have in each case one seat frame that has a holding section for receiving seat fittings and a plurality of supporting elements for coupling to a floor ; and - for each passenger seat at least one variable-position device , which for coupling a supporting element to a seat rail is spaced apart from the holding section and which has a base and a retaining device that is able to be releasably fastened to the base and able to be coupled to a supporting element of the seat frame ; wherein the base has a bearing surface for placement on the seat rail in the cabin of the means of transportation , and at least one locking device for locking the base to the seat rail ; wherein the base has a holding device for releasably receiving the retaining device ; wherein the variable-position device is configured to lock the retaining device selectively in a first position or a second position on the holding device , or to release the retaining device , and, when the retaining device is released, to allow movement of the retaining device between the first position and the second position; wherein the base has a first end and a second end, on each of which a stop for defining the first position and the second position is present; and wherein the spacing between the first position and the second position of the variable-position devices on each passenger seat successively increases from a frontmost passenger seat to a rearmost passenger seat . - a plurality of passenger seats which are disposed behind one another and have in each case one seat frame that has a holding section for receiving seat fittings and a plurality of supporting elements for coupling to a floor ; and - for each passenger seat at least one variable-position device , which for coupling a supporting element to a seat rail is spaced apart from the holding section and which has a base and a retaining device that is able to be releasably fastened to the base and able to be coupled to a supporting element of the seat frame ; wherein the base has a bearing surface for placement on the seat rail in the cabin of the means of transportation , and at least one locking device for locking the base to the seat rail ; wherein the base has a holding device for releasably receiving the retaining device ; wherein the variable-position device is configured to lock the retaining device selectively in a first position or a second position on the holding device , or to release the retaining device , and, when the retaining device is released, to allow movement of the retaining device between the first position and the second position; wherein the base has a first end and a second end, on each of which a stop for defining the first position and the second position is present; and wherein the spacing between the first position and the second position of the variable-position devices on each passenger seat successively increases from a frontmost passenger seat to a rearmost passenger seat .
Method for the production of cell-membrane derived nanoparticles comprising the steps of: I) providing from two to four cell cultures, each cell culture being of a different cell line, and collecting a predetermined number of cells from each cell line; II) lysing the predetermined number of cells of each cell line to obtain lysates of each cell line; III) extracting cell membranes from the lysate of each cell line to obtain cell membrane dispersions of each cell line; IV) mixing the cell membrane dispersion of each cell line in amounts so that the corresponding predetermined number of cells collected from each cell line represents from 0.25 to 4 parts of the total number of cells collected in step (I), and adding an aqueous solution or dispersion containing a therapeutic or diagnostic ingredient to obtain a mix dispersion; V) homogenising the mix dispersion at an external air pressure ranging from 0.552 to 1.151 MPa (80 to 167 psi), with a number of passages ranging from 6 to 14, to form a dispersion containing a plurality of nanoparticles; VI) isolating the plurality of nanoparticles from the dispersion containing them. I) providing from two to four cell cultures, each cell culture being of a different cell line, and collecting a predetermined number of cells from each cell line; II) lysing the predetermined number of cells of each cell line to obtain lysates of each cell line; III) extracting cell membranes from the lysate of each cell line to obtain cell membrane dispersions of each cell line; IV) mixing the cell membrane dispersion of each cell line in amounts so that the corresponding predetermined number of cells collected from each cell line represents from 0.25 to 4 parts of the total number of cells collected in step (I), and adding an aqueous solution or dispersion containing a therapeutic or diagnostic ingredient to obtain a mix dispersion; V) homogenising the mix dispersion at an external air pressure ranging from 0.552 to 1.151 MPa (80 to 167 psi), with a number of passages ranging from 6 to 14, to form a dispersion containing a plurality of nanoparticles; VI) isolating the plurality of nanoparticles from the dispersion containing them.
An apparatus for determining the moisture of a sample containing a solid mixture, with - at least one sample chamber for accommodating the sample, - at least one sensor for measuring a characteristic variable of a gas mixture surrounding the sample, and - a determination device for determining the moisture content of the sample from the at least one characteristic variable, characterized by a measuring chamber that can be evacuated into the rough vacuum range by means of an external vacuum pump or a pump of the apparatus , which measuring chamber can be optionally fluidically separated from the at least one sample chamber or connected to the sample chamber by means of a separating fitting of the apparatus , wherein the at least one sensor is set up to measure the characteristic variable of the gas mixture in the measuring chamber . - at least one sample chamber for accommodating the sample, - at least one sensor for measuring a characteristic variable of a gas mixture surrounding the sample, and - a determination device for determining the moisture content of the sample from the at least one characteristic variable, characterized by a measuring chamber that can be evacuated into the rough vacuum range by means of an external vacuum pump or a pump of the apparatus , which measuring chamber can be optionally fluidically separated from the at least one sample chamber or connected to the sample chamber by means of a separating fitting of the apparatus , wherein the at least one sensor is set up to measure the characteristic variable of the gas mixture in the measuring chamber .
A method for radiolabelling a biological targeting molecule which comprises: (i) provision of a protected compound of Formula (IB) Q-[linker]-X 1 (IB) (ii) deprotection of the protected compound of Formula or (IB) of step (i) to give an aminooxy compound of Formula (IIB); Q-[linker]-O-NH 2 (IIB) (iii) condensation of: the aminooxy compound of Formula (IIB) with a carbonyl compound of Formula (IIIB), [BTM]-(C=O)Y 1 (IIIB) to give a radiolabelled conjugate of Formula (IVB): [BTM]-(CY 1 )=N-O-[linker]-Q (IVB) wherein: [BTM] is a biological targeting molecule; X 1 is a protected aminooxy group of formula: wherein R 1 and R 2 are independently chosen from C 1-3 alkyl, C 1-3 fluoroalkyl or C 4-6 aryl; Q is a group which comprises a radioisotope suitable for PET or SPECT imaging in vivo ; Y 1 is H, C 1-6 alkyl or C 4-10 aryl, [linker] is a linker group. (i) provision of a protected compound of Formula (IB) Q-[linker]-X 1 (IB) (ii) deprotection of the protected compound of Formula or (IB) of step (i) to give an aminooxy compound of Formula (IIB); Q-[linker]-O-NH 2 (IIB) (iii) condensation of: the aminooxy compound of Formula (IIB) with a carbonyl compound of Formula (IIIB), [BTM]-(C=O)Y 1 (IIIB) to give a radiolabelled conjugate of Formula (IVB): [BTM]-(CY 1 )=N-O-[linker]-Q (IVB) [BTM] is a biological targeting molecule; X 1 is a protected aminooxy group of formula: wherein R 1 and R 2 are independently chosen from C 1-3 alkyl, C 1-3 fluoroalkyl or C 4-6 aryl; Q is a group which comprises a radioisotope suitable for PET or SPECT imaging in vivo ; Y 1 is H, C 1-6 alkyl or C 4-10 aryl, [linker] is a linker group.
Method for transmitting system information from a base station being part of a wireless cellular network to a user equipment, the user equipment being a limited-bandwidth device, camping on the base station, wherein the system information is divided in a plurality of system information blocks (M-SIBx), which are at least once transmitted during one broadcast channel modification period , characterized in that the minimum broadcast channel modification period for limited-bandwidth devices lasts at least 10,24 seconds, while for a user equipment that is not operating as limited-bandwidth device the minimum broadcast channel modification period is below 10,24 seconds, and wherein the first system information block (M-SIB1) further comprises: - a broadcast channel change notification tag (VT) indicating if a change on the system information has happened, and - an element indicating in which system information block a content change has happened. - a broadcast channel change notification tag (VT) indicating if a change on the system information has happened, and - an element indicating in which system information block a content change has happened.
An aqueous composition for use in an ophthalmic surgery for treating an ocular disease as an ophthalmic surgical aid, wherein the composition comprises chondroitin sulfate, hyaluronic acid, sorbitol, and a pharmaceutically acceptable carrier, and wherein the composition has a viscosity of 20,000 to 120,000 mPa·s at 25°C and at shear rate of 2 s -1 , and wherein the concentration of the sorbitol contained in the composition is 1 mg/mL to 80 mg/mL.
Synthetic jet device comprising: a vibrating membrane disposed between a top cavity and a bottom cavity ; characterised by a lower support disposed between the membrane and a permanent magnet , the lower support having a bottom surface coupled to a top surface of the permanent magnet around a perimeter of the top surface of the permanent magnet; an upper support disposed between the membrane and a top lid , the upper support having a top surface coupled to a bottom surface of the top lid around a perimeter of the bottom surface of top lid; and an opening through the lid to allow puffs of air or liquid to be expelled from the top cavity through the opening when the vibrating membrane vibrates. a vibrating membrane disposed between a top cavity and a bottom cavity ; characterised by a lower support disposed between the membrane and a permanent magnet , the lower support having a bottom surface coupled to a top surface of the permanent magnet around a perimeter of the top surface of the permanent magnet; an upper support disposed between the membrane and a top lid , the upper support having a top surface coupled to a bottom surface of the top lid around a perimeter of the bottom surface of top lid; and an opening through the lid to allow puffs of air or liquid to be expelled from the top cavity through the opening when the vibrating membrane vibrates.